Effects of food and esomeprazole on pharmacokinetics of sevabertinib

Le résumé fourni par la source

Sevabertinib (BAY 2927088) is an oral reversible tyrosine kinase inhibitor being developed for treatment of adult patients with unresectable or metastatic non-small cell lung cancer harboring human epidermal growth factor receptor 2–activating mutations. Sevabertinib is a high-permeability compound with low pH-dependent aqueous solubility. A clinical study was performed to evaluate the pharmacokinetics (PK) of sevabertinib when administered under fasted conditions or following a highor low-fat meal (NCT06378658). The effect of the proton pump inhibitor (PPI) esomeprazole was also evaluated.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.